Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H31FO6 |
| Molecular Weight | 434.4977 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
InChI
InChIKey=YNDXUCZADRHECN-JNQJZLCISA-N
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
| Molecular Formula | C24H31FO6 |
| Molecular Weight | 434.4977 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Triamcinolone acetonide is a synthetic corticosteroid used to treat various skin conditions, and to relieve the discomfort of mouth sores. In nasal spray form, it is used to treat allergic rhinitis. It is a more potent derivative of triamcinolone, and is about eight times as potent as prednisone. TRIESENCE™ is a synthetic corticosteroid indicated for: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Triamcinolone acetonide is a synthetic fluorinated corticosteroid with approximately 8 times the potency of prednisone in animal models of inflammation. Although the precise mechanism of corticosteroid antiallergic action is unknown, corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRIESENCE Approved Use1.1. Ophthalmic Diseases
TRIESENCE™ (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for:
• sympathetic ophthalmia,
• temporal arteritis,
• uveitis, and
• ocular inflammatory conditions unresponsive to topical corticosteroids.
1.2 Visualization during Vitrectomy
TRIESENCE™ is indicated for visualization during vitrectomy. |
|||
| Primary | TRIESENCE Approved Use1.1. Ophthalmic Diseases
TRIESENCE™ (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for:
• sympathetic ophthalmia,
• temporal arteritis,
• uveitis, and
• ocular inflammatory conditions unresponsive to topical corticosteroids.
1.2 Visualization during Vitrectomy
TRIESENCE™ is indicated for visualization during vitrectomy. |
|||
| Primary | TRIESENCE Approved Use1.1. Ophthalmic Diseases
TRIESENCE™ (triamcinolone acetonide injectable suspension) 40 mg/mL is indicated for:
• sympathetic ophthalmia,
• temporal arteritis,
• uveitis, and
• ocular inflammatory conditions unresponsive to topical corticosteroids.
1.2 Visualization during Vitrectomy
TRIESENCE™ is indicated for visualization during vitrectomy. |
|||
| Primary | Nasacort Approved UseNASACORT AQ Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal
and perennial allergic rhinitis in adults and children 2 years of age and older. Launch Date1996 |
|||
| Primary | Nasacort Approved UseNASACORT AQ Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal
and perennial allergic rhinitis in adults and children 2 years of age and older. Launch Date1996 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7608322 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMCINOLONE ACETONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.4 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7608322 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMCINOLONE ACETONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h |
, respiratory |
TRIAMCINOLONE ACETONIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
2.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7608322 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMCINOLONE ACETONIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
29% |
, respiratory |
TRIAMCINOLONE ACETONIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Local atrophy following steroid injection. | 2002-04 |
|
| A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis. | 2002-04 |
|
| [Experience gained with the use of local administration of medicinal remedies in rheumatic diseases]. | 2002-03-08 |
|
| [Steroid sprays in non-infectious rhinitis and sinusitis. Proper and regular spraying does not damage the nasal mucosa]. | 2002-03-07 |
|
| Stealth triamcinolone acetonide in a phytocosmetic cream. | 2002-03 |
|
| Prolonged childhood Cushing's syndrome secondary to intralesional triamcinolone acetonide. | 2002-03 |
|
| Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. | 2002-03 |
|
| Short-term use of intranasal corticosteroids: lack of systemic effects. | 2002-03 |
|
| Release of triamcinolone acetonide from mucoadhesive polymer composed of chitosan and poly(acrylic acid) in vitro. | 2002-03 |
|
| Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. | 2002-02-28 |
|
| Correction of the soft tissue pollybeak using triamcinolone injection. | 2002-02-15 |
|
| Experiences with neurotomies. | 2002-02-01 |
|
| Angiostatic effects of corticosteroid on wound healing of the rabbit ear. | 2002-02 |
|
| Subcutaneous steroid injection as treatment for chalazion: prospective case series. | 2002-02 |
|
| Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in asthma management. | 2002-02 |
|
| Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. | 2002-02 |
|
| Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. | 2002-02 |
|
| Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. | 2002-02 |
|
| [Ropivacaine (naropin), local anesthetic of choice for epidural blockade]. | 2002-01-05 |
|
| Development of a topical suspension containing three active ingredients. | 2002-01 |
|
| A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. | 2002-01 |
|
| Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. | 2002-01 |
|
| Adult-onset limbal juvenile xanthogranuloma. | 2002-01 |
|
| Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. | 2001-12 |
|
| The painful shoulder. | 2001-12 |
|
| Periodontal response to two intracanal medicaments in replanted monkey incisors. | 2001-12 |
|
| Selective nerve root blocks for the treatment of sciatica: evaluation of injection site and effectiveness--a study with patients and cadavers. | 2001-12 |
|
| Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. | 2001-11-06 |
|
| [Post-corticoid atrophy]. | 2001-11 |
|
| Three methods of treatment of chalazia in children. | 2001-11 |
|
| The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. | 2001-11 |
|
| [Intravitreal injection of triamcinolone acetonide in non infectious uveitis]. | 2001-11 |
|
| Once-daily vs twice-daily triamcinolone acetonide cream for psoriasis. | 2001-11 |
|
| Intralesional steroids reduce inflammation from extravasated chemotherapeutic agents. | 2001-10 |
|
| Markers of allergic inflammation in peripheral blood of children with asthma after treatment with inhaled triamcinolone acetonide. | 2001-10 |
|
| Fas mediates apoptosis in steroid-induced myopathy of rats. | 2001-10 |
|
| Intracanal use of a corticosteroid-antibiotic compound for the management of posttreatment endodontic pain. | 2001-10 |
|
| Bone loss accompanying medical therapies. | 2001-09-27 |
|
| Effects of inhaled glucocorticoids on bone density in premenopausal women. | 2001-09-27 |
|
| [Immunological regulations of dendritic cell in abnormal scarring tissue]. | 2001-09 |
|
| [Comparative efficacy of glucocorticoid preparations in the local therapy of inflammatory degenerative diseases of the locomotor apparatus]. | 2001-09 |
|
| The role of ultrasonography in the diagnosis and management of idiopathic plantar fasciitis. | 2001-09 |
|
| Therapeutic options for a 53-year-old black woman with concomitant glaucoma, uveitis, and cataract. | 2001-08 |
|
| Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. | 2001-08 |
|
| Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. | 2001-07 |
|
| Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate. | 2001-06-08 |
|
| Intralesional cryosurgery using lumbar puncture and/or hypodermic needles for large, bulky, recalcitrant keloids. | 2001-05 |
|
| Aerosol characterization of nebulized intranasal glucocorticoid formulations. | 2001 |
|
| The effect of scatter and attenuation on aerosol deposition as determined by gamma scintigraphy. | 2001 |
|
| Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. | 2001 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020468s024lbl.pdf
40 mg/mL
Route of Administration:
Other
In chondrocyte cultures, triamcinolone acetonide (TA) reduced chondrocyte viability in a concentration-dependent manner. Low-molecular-weight hyaluronan (LMWHA) 2.5 mg/ml combined with TA at IC20 (0.09 mg/ml) could increase the viability of normal chondrocytes when compared with TA-treated alone. TA at IC20 induced down-regulation of ACAN and induced up-regulation of ADAMTS5 in canine normal chondrocytes. TA at IC20 (0.11 mg/ml) up-regulated ADAMTS5, MMP2, MMP3, MMP13, and ACAN expression in canine OA chondrocytes. In explant culture, TA at 1.25, 2.5, and 5 mg/ml increased the severity of structural damage, chondrocyte loss and cluster formation, and proteoglycan loss in OA cartilage.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:48 GMT 2025
by
admin
on
Mon Mar 31 17:33:48 GMT 2025
|
| Record UNII |
F446C597KA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
||
|
NDF-RT |
N0000175576
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/15/1490
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
76-25-5
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
DBSALT000860
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
100000090386
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
10761
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID6021371
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
SUB04936MIG
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
6436
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
D014222
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
1677002
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
m11028
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
F446C597KA
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
71418
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
TRIAMCINOLONE ACETONIDE
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
200-948-7
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
C48027
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
F446C597KA
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL1504
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
21916
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY | |||
|
2726
Created by
admin on Mon Mar 31 17:33:48 GMT 2025 , Edited by admin on Mon Mar 31 17:33:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
FECAL; PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL; PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL; PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT | |||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|